Loading…
Hosted by Flot.bio · 🇺🇸 US · EN-US · 56 episodes
Established thought leaders with verified media credentials.
Watch the #1 Biotech Podcast in Europe to grow. Hosted by Philip Hemme. 25k monthly views. Free.Guests include Antoine Papiernik @Sofinnova, Werner Lanthaler @Evotec, Ingmar Hoerr @CureVac, Bernat Olle @Vedanta, Johannes Fruehauf @BioLabs, Rodger Novak @CRISPR Tx, Agnete Fredriksen @Nykode, Mike Ward, Thomas Clozel @Owkin, Marc de Garidel @Abivax, Sander van Deventer @VectorY & Forbion, Jens Nielsen @BII, Edwin Moses, Bahija Jallal @Immunocore, and more. Your host Philip animates the conversation to dig out exciting, and sometimes contrarian, ideas.
Flot.bio hosts Flot.bio x Philip Hemme, a science show with 56 episodes published.
Christian Angermayer became a multimillionaire before turning 25 thanks to the merger of Alnylam with Ribopharma. We talk about his diverse investment appetite and the rise of consumer biotech and human enhancement.We ta
After ImCheck’s inception in 2015, Pierre took the helm through clinical development and guided the startup to a $1.2B buyout by Ipsen last year. In a session at the Kadans Oncology Summit, he talks about how the exit ma
![CEO Jean-François Brepson on Scaling a CRO, and Selling to Charles River | E59 [Sponsored] episode artwork](https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/38602414/38602414-1781434773704-76b86199b868b.jpg)
Founded in 2010, the Institut Pasteur spinout PathoQuest sold to top CRO Charles River for $70M this year, a product of years of collaboration and stepwise investments.Jean‑François tells us how the exit unfolded, as wel
When Hervé joined Incyte in 2014, the launch of lead product Jakafi in the US was a little choppy. By the time he left in 2025, he had grown their revenue from $300 million to a whopping $5 billion. We also talk about th
We admire the mountains of Austria with the co-founder of Curie.Bio, a founder-friendly fund that now manages $1.25B and backs 38 portfolio companies.We discuss Curie.Bio’s track record, with its most advanced portfolio
Forbion celebrates its 20th anniversary this year, with a whopping €5 billion raised so far. Sander marks the occasion by discussing how Forbion plans to promote life sciences investments in Europe via the Life Sciences
![Solving Antimicrobial Resistance, Vaccines, Antibiotics | Immunethep 🇵🇹 | E55 [Sponsored] episode artwork](https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/38602414/38602414-1775472100828-2b361bd18cd64.jpg)
Antibiotic-resistant superbugs could become a greater threat than cancer. Bruno and Pedro at the startup Immunethep explain how they’re tackling the crisis with vaccines. We discuss how Immunethep could challenge Pfizer’
We dive into Bial’s meteoric journey from a small pharmacy in Porto to Portugal’s biggest biopharma company, all while still being 100% family owned. We cover Bial’s pipeline, including treatments for epilepsy and Parkin
Novonesis arose from a 2023 merger of Novozymes and Chr Hansen, and is a highly profitable powerhouse. CSO Claus talks about the applications of Novonesis’ technology, its low profile among consumers, and how hard it is
![Sten R. Sörensen, Cereno Scientific 🇸🇪 | Drug Repurposing, Retail Investors | E52 [Sponsored] episode artwork](https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/38602414/38602414-1770668818564-0e3602876c1a2.jpg)
At the beginning of 2025, Sten R. Sörensen announced Cereno Scientific’s positive Phase 2a results in PAH for lead asset CS1. He’s now moving forward with a global Phase 2b trial starting in Q2 2026. The company also pro
Founded in 1991, Camurus has grown into a $4B biotech with two products in the market, a rich pipeline, and 290 employees.Fredrik explains how Camurus’ long-acting injections — part of its FluidCrystal technology — breat
Founded in 1979, Transgene has transformed itself into a leading personalized cancer vaccine player. Alessandro talks about the transformation, his history in cell therapy and how Europe’s biotech space can rival those o
Pascal Touchon unpacks why the next CAR-T innovations, including allogeneic and in vivo therapies, are going to be so exciting. The cell therapy master outlines his central role in bringing two first‑in‑class cell therap
Why have early AI drug-discovery companies often overpromised but underdelivered? Biology is still complex and hard to solve, Werner told Philip in Vienna.We revisit Werner in Vienna after he left Evotec and went on a sa
Valneva now has three commercialized vaccines, and a Lyme disease candidate in Phase 3. Philip quizzes CEO Thomas Lingelbach about everything. They also discuss the current political turbulence with vaccines, especially
When Abivax released stunning phase 3 results for ulcerative colitis, its 600% stock price surge froze Euronext for 45 minutes. Philip meets Abivax CEO Marc de Garidel in Vienna, Austria, to go behind the scenes of a rem
As Philip travels to France, Nanobiotix CEO Laurent Lévy discusses how the company broke into Europe’s exclusive $1 billion biotech club, alongside the likes of Abivax and Medincell. They also chat about what it means to
![Gerrit Sitters, LUMICKS 🇳🇱 | CAR-T therapy, Single-Cell Analysis | E44 [Sponsored] episode artwork](https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/38602414/38602414-1761656173185-1b6b26ad3d84f.jpg)
As Philip tours Amsterdam, he visits the biotech tools startup LUMICKS. Founded in 2014, the firm offers products analyzing the binding interactions between molecules and cells, with applications in drug development, CAR
We travel to the offices of Pharming Group in Leiden, the Netherlands, to chat with the newcomer CEO Fabrice Chouraqui. Fabrice discusses the fascinating history of Pharming, with its first commercial drug RUCONEST produ
![Daniela Marino, CUTISS 🇨🇭 | Tissue Engineering, Skin Grafts | E42 [Sponsored] episode artwork](https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/38602414/38602414-1760100499710-07ef45d87403b.jpg)
Hot on the heels of CUTISS’ $60M Series C round, we catch up once more with CEO and co-founder Daniela Marino. We chat about the company’s mission to develop an engineered tissue therapy to reduce the need for skin graft
Detected from recent episode content. Sponsor presence is a real signal of listener purchasing power and show monetisation.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
Flot.bio x Philip Hemme has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their science audience.
Flot.bio x Philip Hemme is hosted by Flot.bio. The show is categorised under science (life) and has published 56 episodes.
Flot.bio x Philip Hemme has published 56 episodes.
Flot.bio x Philip Hemme regularly covers science, life. It sits in the science category, with a life focus.
Flot.bio x Philip Hemme is accessible for guests with genuine science expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
Flot.bio x Philip Hemme hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of Flot.bio x Philip Hemme average 63 minutes, giving guests a long-form format with plenty of time to expand on their expertise.
Our data rates Flot.bio x Philip Hemme's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 11 days ago.